摘要
目的探讨癌基因C－erbB_2，在宫颈癌组织中表达的临床、病理及预后的关系。方法采用免疫组织化学方法，检测C-erbB_2在宫颈癌组织中表达情况，鳞癌87例，腺癌12例，正常宫颈组织8例，临床Ⅱ期4例，Ⅲ期95例。结果阳性染色定位细胞膜，87例鳞癌、12例腺癌，阳性率分别为58％、66％．正常宫颈组织明性。组织学1、2、3级阳性率分别为46％、56％、70．8％。临床Ⅱ期阳性率25％明显低于Ⅲ期61％。预后存活10年以上C－erbB_2阳性率47％，明显低于1年内死亡72．9％，P＜0．01。结论C－erbB_2蛋白高表达渴望成为一项估计宫颈癌患者预后的指标之一。
Objective To investigate the relationship between C-erbB_2, oncoprotein expressionwith clini-pathology and prognosis of cervical cancer. Methods Immunohistochemistry was used to ex-amine the C-erbB_2, oncoprotein in 87 cases of cervical squamous cell carcinoma, 12 cases of cervical ade-nocarcinoma and of 8 cases of normal cervical tissues. Results Definite membrane staining in squamouscell carcinoma and adenocarcinoma positive staining rate of C-erbB_2 oncoprotein expression was 58 % and66%. None of normal cervical tissues showed positive of C-erbB_2, oncoprotein. At clinical stage Ⅱ theexpression of C-erbB_2 was lower (25 % ) than at stage Ⅲ (61%). Histologic grade Ⅰ, Ⅱ and grade Ⅲ pos-itive staining rate was 40%, 56% and 70. 8 %. The rate of C-erbB_2 positive in 1O years survival groupwas much lower than that in one year survival group (P＜0. 01). Conclusion The expression of the C-erbB_2 oncoprotein was associated with poorer prognosis of patients with cervical cancer. These findingsraise the possibility that immunostaining of C-erbB_2, oncoprotein colud be used as a prognostic marker.
出处
《中国全科医学》
CAS
CSCD
1999年第3期180-182,共3页
Chinese General Practice
基金
山西省攻关项目
关键词
宫颈癌
免疫组化
C-ERBB2
临床
病理
预后
Cervical Cancer Immunohistochemistry C-erbB_2, Clinic Pathology Prognosis
